Lindy P. Fox

Guest Editor for the following articles:

Dec
2006
Vol. 25. No. 4

Emerging Dermatologic Issues in the Oncology Patient

Steven R. Mays, MD | Philip R Cohen, MD

The spectrum of skin diseases that occurs in the oncology patient differs somewhat from that seen in other immunosuppressed populations. We review the cutaneous manifestations of invasive mold infections in the leukemia/lymphoma population.

MORE
Mar
2017
Vol. 36. No. 1

The efficient, effective community hospital inpatient dermatology consult

Lindsay Ackerman, MD | Margaret A Kessler, MD

Inpatient hospital consult dermatology (inpatient dermatology), as considered by private practicing dermatologists, remains an often under-recognized, overlooked, and yet extremely important aspect of dermatology as a medical subspecialty.

MORE
Sep
2007
Vol. 26. No. 3

Approach to the Patient With a Suspected Drug Eruption

Jonathan Cotliar, MD

Diagnosis and management of adverse drug reactions constitutes a significant portion of U.S. health care costs. The clinical presentation of these reactions varies from self-limited, morbilliform drug eruptions to more severe, systemic reactions, such as drug hypersensitivity syndromes, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which are associated with significant mortality.

MORE
Mar
2014
Vol. 33. No. 1

Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology

Joanna L. Harp, MD | Kanade Shinkai, MD | Melissa A. Kinnebrew, PhD

Severe cutaneous adverse reactions, though rare, represent
a mucocutaneous presentation of adverse drug
responses associated with significant morbidity and mortality.
Here, we review the recent literature highlighting the
roles of selective immune responses, genetic factors, and
drug metabolism in increasing susceptibility of a given
patient to these rare and severe reactions. Further understanding
of these factors and their relative contributions to
a severe drug reaction may hold important implications
for future patient-specific pharmacogenomic and immunologic
profiling in an effort to personalize prescribing patterns
by clinicians. Emerging concepts, such as the role of
viral reactivation and the presence of overlapping clinical
features in severe drug eruptions, are also discussed.

MORE
Mar
2017
Vol. 36. No. 1

Teledermatology in the inpatient setting

Rechelle Tull, BS | Karolyn A Wanat, MD
Use of TD in the inpatient setting is emerging as a potentially effective method of triage, assistance, or providing dermatologic consultative services.
MORE